Get the Stockscreener App
3.35
0.60%
0.02
Polypid Ltd stock is traded at $3.35, with a volume of 8,572.
It is up +0.60% in the last 24 hours and down -6.56% over the past month.
PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. Its product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.
See More
Previous Close:
$3.33
Open:
$3.37
24h Volume:
8,572
Relative Volume:
1.34
Market Cap:
$22.03M
Revenue:
-
Net Income/Loss:
$-23.87M
P/E Ratio:
-0.0923
EPS:
-36.3
Net Cash Flow:
$-47.63M
1W Performance:
-4.01%
1M Performance:
-6.56%
6M Performance:
-32.19%
1Y Performance:
-17.28%
1-Day Range:
$3.2378
$3.5856
1-Week Range:
$3.20
$3.66
52-Week Range:
$2.95
$9.20
Polypid Ltd Stock (PYPD) Company Profile
Polypid Ltd Stock (PYPD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-14-21 | Initiated | JMP Securities | Mkt Outperform |
| Jul-30-21 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-24-20 | Upgrade | Raymond James | Outperform → Strong Buy |
| Aug-10-20 | Initiated | Alliance Global Partners | Buy |
| Jul-21-20 | Initiated | BMO Capital Markets | Outperform |
| Jul-21-20 | Initiated | Barclays | Overweight |
| Jul-21-20 | Initiated | Raymond James | Outperform |
View All
Polypid Ltd Stock (PYPD) Latest News
PolyPid shares rise on strong Phase 3 prospects, gets buy rating - Investing.com Canada
PolyPid to Report Third Quarter 2024 Financial Results and Operational Highlights on November 13, 2024 - GlobeNewswire
Will PolyPid Wield The SHIELD? - RTTNews
Rosalind Advisors, Inc. Reduces Stake in PolyPid Ltd - GuruFocus.com
PolyPid Announces Publication in International Journal of - GlobeNewswire
PolyPid Announces Publication in International Journal of Surgery Highlighting Results of Phase 3 SHIELD I Trial of D-PLEX₁₀₀ in Prevention of Surgical Site Infections in Abdominal Colorectal Surgery - StockTitan
PolyPid retains stock target, buy rating on positive trial enrollment update By Investing.com - Investing.com South Africa
PolyPid retains stock target, buy rating on positive trial enrollment update - Investing.com India
PolyPid completes enrollment for phase 3 trial - Investing.com
PolyPid Nears Completion of Key Phase 3 Trial - TipRanks
PolyPid Announces Last Patient In for Planned Unblinded - GlobeNewswire
PolyPid Announces Last Patient In for Planned Unblinded Interim Analysis in the Ongoing SHIELD II Phase 3 Trial Evaluating D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site Infections - StockTitan
PolyPid to Participate in Three Upcoming Fall Investor Conferences - GlobeNewswire
Equities Analysts Offer Predictions for PolyPid Ltd.’s Q3 2024 Earnings (NASDAQ:PYPD) - Defense World
HC Wainwright Reiterates “Buy” Rating for PolyPid (NASDAQ:PYPD) - Defense World
PolyPid Ltd. (NASDAQ:PYPD) Q2 2024 Earnings Call Transcript - Insider Monkey
Earnings call: PolyPid reports a net loss of $6.3 million in the second-quarter of 2024 - Investing.com
PolyPid Reports Growth in Mid-Year Assets - TipRanks
PolyPid Advances SHIELD II Trial with Solid Financing - TipRanks
PolyPid Provides Corporate Update and Reports Second Quarter 2024 Financial Results - GlobeNewswire
Analyzing Silk Road Medical (NASDAQ:SILK) & PolyPid (NASDAQ:PYPD) - Defense World
PolyPid (PYPD) Scheduled to Post Earnings on Wednesday - Defense World
PolyPid secures $14 million in private placement - Investing.com
PolyPid secures $14 million in private placement By Investing.com - Investing.com UK
PolyPid Secures Funding, Extends Runway for D-PLEX100 Trial - TipRanks
PolyPid Announces Private Placement for Up to $14 Million in Gross Proceeds - StockTitan
PolyPid to Report Second Quarter 2024 Financial Results and Operational Highlights on August 14, 2024 - GlobeNewswire
PolyPid stock hits 52-week low at $3.35 amid market challenges - Investing.com
PolyPid (NASDAQ:PYPD) Trading 1.7% Higher - Defense World
PolyPid Ends Equity Sales Agreement, No Penalties Incurred - TipRanks
PolyPid Revamps Share Option Plan for Stakeholders - TipRanks
Critical Comparison: PolyPid (NASDAQ:PYPD) versus GBS (NYSE:GBS) - Defense World
PolyPid Ltd. (NASDAQ:PYPD) Forecasted to Post Q2 2024 Earnings of ($1.51) Per Share - Defense World
PolyPid hosts KOL call, provides update on ongoing SHIELD II Phase 3 trialTipRanks.com - TipRanks
Superficial Punctate Keratitis Market Size 2032 | Market Drivers & Barriers, Clinical Trials and Latest Drugs - EIN News
PolyPid Advances Trial for Infection PreventionTipRanks.com - TipRanks
PolyPid Hosts KOL Call to Discuss Significant Unmet Medical Need in Surgical Site Infections Prevention and Provides ... - GlobeNewswire
PolyPid Hosts KOL Call to Discuss Significant Unmet Medical - GlobeNewswire
Comparing PolyPid (NASDAQ:PYPD) and Nemaura Medical (NASDAQ:NMRD) - Defense World
PolyPid to Host Virtual KOL Event on June 17, 2024, and Provide an Update on the Company's Ongoing D-PLEX₁₀₀ ... - GlobeNewswire
Wall Street Analysts Think PolyPid Ltd. (PYPD) Could Surge 289%: Read This Before Placing a Bet - Yahoo News UK
PolyPid Ltd. Schedules Shareholder MeetingTipRanks.com - TipRanks
PolyPid Enhances Share Option Plan to Motivate StaffTipRanks.com - TipRanks
Is Liquidia Technologies (LQDA) Outperforming Other Medical Stocks This Year? - Yahoo News UK
PolyPid (NASDAQ:PYPD) Earns Buy Rating from HC Wainwright - Defense World
How Much Of PolyPid Ltd. (NASDAQ:PYPD) Do Insiders Own? - Yahoo Lifestyle UK
Polypid Ltd Stock (PYPD) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.75%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):